Company Overview and News

China’s paper product makers raise prices on higher raw material costs

2018-02-27 scmp
China is likely to see price rises for paper products this year on a shortage of raw materials and imported waste paper, according to Hong Kong-listed Nine Dragons, one of Asia’s largest packaging and paper producers.

China’s tissue giant Vinda expects further industry consolidation as Beijing tightens environmental controls

2018-01-26 scmp
The company forecasts 700,000 tonnes of production capacity will shut down in 2018, a rise from last year’s 600,000 tonnes

DHL/SCMP Hong Kong Business Awards kick off

2016-06-14 scmp
The DHL/SCMP Hong Kong Business Awards 2016 was launched on Monday and is now open for nomination until August 12. The winners will be announced at an awards ceremony on December 1. At the launch lunch on Monday were (front from left) Raymond Yip, deputy executive director of the Hong Kong Trade Development Council; Jeffrey Chan, divisional president for greater China at CPA Australia; Peggy Sito, deputy business editor of the South China Morning Post; Herbert Vongpusanachai, senior vice-president and managing director of DHL Express Hong Kong and Macau; Richard Wong Yue-chim, a professor at the University of Hong Kong; Albert Chan, head of commercial banking at HSBC; (back from left) Ronald Kan, 2016 acting president of the Junior Chamber International Hong Kong; Venus Wong, assistant corporate affairs manager of Vinda International Holdings; Helen Chan Hei-ling, chief executive of Vita Green Health Products; William Shum, founder and chief executive of Memorigin Watch; and Billy Chu, founder and executive director of On Stage Events & Communications.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...